Enteric-coated chromium polynicotinate compositions and uses thereof

• US 6,100,250 A
• Filed: 01/12/1999
• Issued: 08/08/2000
• Est. Priority Date: 08/28/1998
• Status: Expired due to Term

• Current Assignee: Nutrition21 LLC
• Original Assignee: Ambi, Inc. (NXXI, Inc.)
• Inventors: Price, Fredric D., Komorowski, James R., Skluth, Lauren K., de la Harpe, Jon, Chakrin, Lawrence W.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US09/229,463
• Time in Patent Office: 574 Days
• Field of Search: 424/195.1, 514/188
• US Class Current: 514/188
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/09 having two or more such linkages
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/375 Ascorbic acid, i.e. vitamin C; Salts thereof
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 31/7004 Monosaccharides having only carbon, hydrogen and oxygen atoms
• CPC Class Codes: A61P 21/06 Anabolic agents androgens A61P5/26
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48

Abstract

Compositions comprising chromic tripicolinate or chromic polynicotinate in the form of enteric-coated tablets, capsules or microbeads, optionally in combination with nicotinic acid, picolinic acid or both nicotinic acid and picolinic acid. The compositions are useful for supplementing dietary chromium, lowering blood glucose levels, lowering serum lipid levels and increasing lean body mass.

Claims

1. A composition for supplementing dietary chromium and facilitating absorption of essential metals, said composition comprising an enteric-coated chromic polynicotinate pharmaceutical formulation.

2. The composition of claim 1, wherein said pharmaceutical formulation is selected from the group consisting of a tablet, capsule and microbead.

3. The composition of claim 2, wherein the microbead is a sugar beadlet or microcrystalline cellulose beadlet and said chromic polynicotinate is coated on said beadlet.

4. The composition of claim 1, further comprising a cyclooxygenase inhibitor.

21. The composition of claim 1, further comprising an acid.

22. The composition of claim 1, further comprising a mucolytic.

23. The composition of claim 1, further comprising a salicin-containing herb.

5. A method for supplementing dietary chromium in an individual, comprising orally administering to said individual a composition comprising an enteric-coated chromic polynicotinate pharmaceutical formulation.

6. The method of claim 5, wherein said pharmaceutical formulation is selected from the group consisting of a tablet, capsule and microbead.

7. The method of claim 6, wherein the microbead is a sugar beadlet or microcrystalline cellulose beadlet and said chromic polynicotinate is coated on said beadlet.

8. The method of claim 5, wherein said composition further comprises a cyclooxygenase inhibitor.

24. The method of claim 5, wherein said composition further comprises an acid.

25. The method of claim 5, wherein said composition further comprises a mucolytic.

26. The method of claim 5, wherein said composition further comprises a salicin-containing herb.

9. A method for reducing hyperglycemia and stabilizing serum glucose levels in an individual in need thereof, comprising orally administering to said individual an effective daily hyperglycemia-reducing amount of a composition comprising an enteric-coated chromic polynicotinate pharmaceutical formulation.

10. The method of claim 9, wherein said pharmaceutical formulation is selected from the group consisting of a tablet, capsule and microbead.

11. The method of claim 10, wherein said microbead is a sugar beadlet or microcrystalline cellulose beadlet and said chromic polynicotinate is coated on said beadlet.

12. The method of claim 9, wherein said composition comprises a cyclooxygenase inhibitor.

27. The method of claim 9, wherein said composition further comprises an acid.

28. The method of claim 9, wherein said composition further comprises a mucolytic.

29. The method of claim 9, wherein said composition further comprises a salicin-containing herb.

13. A method for increasing lean body mass and reducing body fat of an individual in need thereof, comprising orally administering to said individual an effective, lean body mass-increasing amount of a composition comprising an enteric-coated chromic polynicotinate pharmaceutical formulation.

14. The method of claim 13, wherein said pharmaceutical formulation is selected from the group consisting of a tablet, capsule and microbead.

15. The method of claim 14, wherein said microbead is a sugar beadlet or microcrystalline cellulose beadlet and said chromic polynicotinate is coated on said beadlet.

16. The method of claim 13, wherein said composition comprises a cyclooxygenase inhibitor.

30. The method of claim 13, wherein said composition further comprises an acid.

31. The method of claim 13, wherein said composition further comprises a mucolytic.

32. The method of claim 13, wherein said composition further comprises a salicin-containing herb.

17. A method for reducing high levels of blood serum lipids in an individual in need thereof, comprising administering to said individual an effective blood serum lipid-reducing amount of a composition comprising an enteric-coated chromic polynicotinate pharmaceutical formulation.

18. The method of claim 17, wherein said pharmaceutical formulation is selected from the group consisting of a tablet, capsule and microbead.

19. The method of claim 18, wherein said microbead is a sugar beadlet or microcrystalline cellulose beadlet and said chromic polynicotinate is coated on said beadlet.

20. The method of claim 17, wherein said composition comprises a cyclooxygenase inhibitor.

33. The method of claim 17, wherein said composition further comprises an acid.

34. The method of claim 17, wherein said composition further comprises a mucolytic.

35. The method of claim 17, wherein said composition further comprises a salicin-containing herb.